List of Excipients in Branded Drug AK-CON

« Back to Dashboard

Generic Drugs Containing AK-CON

Company	Ingredient	NDC	Excipient
Rebel Distributors Corp	naphazoline hydrochloride	21695-915	BENZALKONIUM CHLORIDE
Rebel Distributors Corp	naphazoline hydrochloride	21695-915	BORIC ACID
Rebel Distributors Corp	naphazoline hydrochloride	21695-915	EDETATE DISODIUM
Rebel Distributors Corp	naphazoline hydrochloride	21695-915	HYDROCHLORIC ACID
Rebel Distributors Corp	naphazoline hydrochloride	21695-915	SODIUM CARBONATE
Rebel Distributors Corp	naphazoline hydrochloride	21695-915	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in AK-CON?

# Of NDCs	Excipient
1	BENZALKONIUM CHLORIDE
1	BORIC ACID
1	EDETATE DISODIUM
1	HYDROCHLORIC ACID
1	SODIUM CARBONATE
1	SODIUM CHLORIDE

AK-CON Excipient Strategy and Commercial Opportunities for Naphazoline Ophthalmic Products

Last updated: August 22, 2026

AK-CON is a naphazoline hydrochloride ophthalmic solution used as an ocular vasoconstrictor for temporary relief of eye redness. Its commercial opportunity is primarily formulation-driven rather than molecule-driven. The strongest opportunities are preservative-free delivery, reduced ocular-surface irritation, multidose container technology, improved patient adherence, and differentiated positioning against lower-strength over-the-counter redness relievers.

What is AK-CON and which excipients does it contain?

AK-CON contains naphazoline hydrochloride 0.1% in an ophthalmic solution. The product is labeled for topical ocular use and is supplied in a sterile dropper bottle. The publicly available labeling identifies the following inactive ingredients:

Excipient or formulation component	Functional role
Benzalkonium chloride	Preservative
Boric acid	Buffering and tonicity contribution
Sodium borate	Buffering agent
Sodium chloride	Tonicity adjustment
Edetate disodium	Chelating agent; supports preservative performance
Purified water	Vehicle
Hydrochloric acid and sodium hydroxide	pH adjustment

The formulation uses benzalkonium chloride, commonly abbreviated BAK, as its antimicrobial preservative. BAK is widely used in ophthalmic products but has commercial limitations in chronic or repeated-use settings because exposure can aggravate ocular-surface disease, particularly in patients with dry eye or compromised corneal epithelium.[1]

AK-CON is distinct from AKORN’s AK-CON-A product, which combines naphazoline hydrochloride with pheniramine maleate for redness and itching associated with allergies. Excipient strategy for AK-CON should not be transferred directly to AK-CON-A because the second active ingredient changes pH, solubility, preservative demand, labeling, and clinical positioning.

What excipient strategy is used in AK-CON?

The current strategy is a conventional preserved aqueous ophthalmic solution. It prioritizes low manufacturing complexity, chemical stability, microbial control, and compatibility with a multidose bottle.

Preservative system

BAK is the principal preservative. Edetate disodium can improve antimicrobial performance by binding divalent metal ions and weakening microbial cell membranes. This allows the preservative system to operate in a relatively simple aqueous vehicle.

The commercial advantage is manufacturing familiarity. The limitation is that the same preservative can reduce differentiation against newer ophthalmic products marketed as BAK-free or preservative-free.

Buffer system

Boric acid and sodium borate provide buffering capacity. The formulation also uses hydrochloric acid and sodium hydroxide to establish the final pH. Buffer selection affects:

• Naphazoline chemical stability
• Ocular comfort
• Corneal tolerability
• Preservative efficacy
• Container compatibility
• Precipitation risk during storage

A replacement formulation would need to preserve naphazoline solubility while maintaining acceptable ocular comfort and antimicrobial protection.

Tonicity control

Sodium chloride adjusts osmolality toward an ophthalmically acceptable range. Borate components also contribute to total ionic strength. Excessive deviation from tear osmolarity can cause transient stinging, reflex tearing, and reduced patient acceptance.

For a reformulation, osmolality should be controlled as a product-quality attribute rather than treated as a secondary excipient parameter. Small changes in active concentration, buffer strength, and preservative system can materially affect osmolality.

What are the main commercial opportunities for AK-CON excipient reformulation?

The largest opportunities are BAK-free multidose packaging, preservative-free unit-dose packaging, and ocular-surface comfort positioning.

Preservative-free AK-CON

A preservative-free version could use unit-dose vials, blow-fill-seal ampoules, or a validated preservative-free multidose dispenser. This approach would target:

• Patients with dry eye
• Patients using multiple ophthalmic products
• Patients requiring frequent administration
• Ophthalmology practices seeking lower-preservative regimens
• Pharmacies and health systems with preservative-free formularies

The main tradeoff is cost. Unit-dose packaging increases material use, filling complexity, shipping volume, and waste. A commercial product would need to justify a higher price through improved tolerability, better adherence, or a defined clinical segment.

BAK-free multidose packaging

A BAK-free multidose system can offer convenience without the waste associated with single-use vials. Technologies may include:

• One-way valves
• Sterile air filtration
• Collapsible containers
• Preservative-free pump dispensers
• Tip designs that limit microbial ingress

The regulatory burden is higher than for a conventional preserved bottle. The manufacturer must demonstrate container-closure integrity, microbial robustness after opening, delivered-dose consistency, extractables and leachables control, and stability throughout the in-use period.

Alternative preservatives

Potential alternatives include polyquaternium-1, stabilized oxychloro complex, oxidative preservative systems, and other ophthalmic antimicrobial systems. Each creates formulation and regulatory work.

A substitute preservative must be assessed for:

• Antimicrobial effectiveness
• Ocular-surface tolerability
• Compatibility with naphazoline
• Adsorption to the container
• Degradation products
• pH sensitivity
• Compatibility with edetate or other chelators

Replacing BAK alone is unlikely to create a defensible commercial product. The stronger opportunity is a complete formulation and delivery-system package supported by comparative tolerability data.

What formulations could be protected around AK-CON?

The naphazoline molecule itself is old and has limited composition-of-matter value. Commercial exclusivity would more likely depend on formulation, container, manufacturing process, or method-of-use claims.

Potential claim areas include:

Claim area	Possible protection
Preservative-free solution	Specific excipient concentrations, pH, osmolality, and stability profile
Multidose delivery	Container and valve configuration that maintains sterility without preservative
Reduced-irritation formulation	Defined BAK-free or low-preservative composition
Enhanced stability	Chelator-buffer combinations that limit degradation
Low-volume delivery	Metered-dose dispenser delivering a controlled ophthalmic dose
Packaging compatibility	Container materials that reduce adsorption or leachables
Manufacturing process	Sterile filtration, aseptic filling, or terminal sterilization parameters
Method of use	Use in patients with ocular-surface sensitivity or dry eye

A patent strategy would need to claim measurable technical differences. Broad claims covering any naphazoline ophthalmic solution would face substantial validity risk because the active ingredient, ophthalmic use, conventional buffers, sodium chloride, and BAK preservation are well established.

The more defensible structure would combine narrow composition claims with device claims and stability data. A formulation patent could be stronger if it demonstrates an unexpected result, such as materially improved stability, lower irritation, extended in-use sterility, or reduced preservative concentration without loss of antimicrobial protection.

What is the FDA regulatory status of AK-CON?

AK-CON is labeled as a prescription ophthalmic product containing naphazoline hydrochloride 0.1%. The product label identifies naphazoline hydrochloride as the active ingredient and lists the ophthalmic solution excipients described above.[1]

Naphazoline is also used in lower-strength nonprescription ocular redness-relief products. The regulatory distinction is important:

• AK-CON is associated with a 0.1% ophthalmic solution.
• Many OTC redness-relief products use lower naphazoline concentrations or different active ingredients.
• A reformulated AK-CON may require an abbreviated new drug application, a suitability pathway, or another FDA pathway depending on the reference product, dosage form, strength, labeling, and listed drug status.
• A switch from prescription to OTC status would require separate regulatory analysis and compliant consumer labeling.

The FDA’s Orange Book should be checked for current reference-listed-drug status, patent listings, exclusivity, and any relevant therapeutic-equivalence designations.[2] Public labeling alone does not establish a current Orange Book patent position.

What patents protect AK-CON and when does AK-CON lose exclusivity?

No reliable conclusion should be drawn from the brand name alone. Patent protection must be assessed against the specific NDA or listed drug entry, not simply against AK-CON marketing materials.

For an older naphazoline ophthalmic product, the expected exclusivity profile is:

Exclusivity category	Commercial relevance
Composition-of-matter patent	Unlikely to remain relevant for naphazoline
Product-specific formulation patent	Possible, but requires verified patent records
Container or delivery patent	Potentially relevant to a reformulated product
Method-of-use patent	Possible for a narrowly defined clinical use
Regulatory exclusivity	Must be verified in the Orange Book and FDA records
Trade secret protection	Relevant to manufacturing and scale-up, not direct generic blocking

A Paragraph IV challenge would be relevant only if an ANDA applicant identifies a listed patent and certifies that the patent is invalid, unenforceable, or will not be infringed. For a legacy ophthalmic solution, generic competition may arise through ordinary ANDA filing if no blocking patent remains.

What does Paragraph IV risk look like for AK-CON?

Paragraph IV risk is likely to center on formulation or device patents rather than the naphazoline active ingredient. The most credible challenge points would include:

• Anticipation by older ophthalmic solutions
• Obviousness of conventional buffer and tonicity systems
• Lack of unexpected results
• Inherent disclosure of pH or osmolality
• Design-around of container claims
• Failure to show non-obvious preservative performance

If the listed product has no active patent barriers, the primary commercial risk is generic substitution and price compression rather than patent litigation.

How strong is the AK-CON patent estate?

The apparent patent estate is weak at the active-ingredient level and potentially moderate only where a company has developed a differentiated delivery system.

A practical scoring framework is:

Estate component	Relative strength
Naphazoline composition of matter	Low
Conventional aqueous solution	Low
BAK-preserved formulation	Low to moderate
Preservative-free multidose system	Moderate to high if technically validated
Unit-dose packaging	Moderate, with design-around risk
Manufacturing process	Moderate as trade secret; variable as patent
Narrow method of use	Moderate if clinically differentiated
Brand and distribution	Commercial value without patent exclusivity

A stronger asset would require clinical or human-factor evidence showing that the excipient change produces a meaningful benefit. Stability data alone may support regulatory approval but may not create a durable market advantage.

Which companies could challenge or compete with AK-CON?

Competition exists across prescription ophthalmic products, OTC redness relievers, allergy combinations, and preservative-free delivery systems.

Relevant competitive groups include:

• Generic ophthalmic manufacturers
• OTC eye-care companies
• Branded allergy-eye-drop companies
• Contract development and manufacturing organizations
• Specialty ophthalmology companies
• Device companies supplying preservative-free multidose dispensers

Potential competitors may offer tetrahydrozoline, phenylephrine, naphazoline, ketotifen, olopatadine, or combination products. Products containing antihistamines compete for patients whose redness is linked to ocular allergy rather than nonspecific vasodilation.

The most direct commercial threat is a therapeutically equivalent generic naphazoline ophthalmic solution. The most important differentiated threat is a preservative-free or BAK-free product with superior tolerability and a stronger ophthalmology-channel strategy.

How does AK-CON compare with OTC redness-relief products?

Attribute	AK-CON	Typical OTC redness-relief product
Active ingredient	Naphazoline hydrochloride 0.1%	Often lower-strength naphazoline, tetrahydrozoline, or phenylephrine
Regulatory positioning	Prescription labeling	Consumer OTC labeling
Preservative	BAK in current labeled formulation	Product-dependent
Primary use	Temporary ocular redness relief	Temporary redness relief
Differentiation	Strength, prescription channel, established formulation	Convenience, price, retail availability
Reformulation opportunity	BAK-free or preservative-free delivery	Comfort, safety, and consumer packaging
Main risk	Generic substitution and price pressure	Brand commoditization and retailer competition

High-strength prescription positioning does not automatically create premium value. The product needs a defined clinical rationale, such as specialist-directed use, preservative avoidance, or a delivery benefit.

What manufacturing and intellectual-property barriers affect AK-CON?

The principal manufacturing barriers are sterile ophthalmic production, fill-finish capacity, preservative efficacy, and container performance.

A commercial reformulation would require control of:

• Sterile filtration and aseptic filling
• Bioburden and endotoxin limits
• Drop-size uniformity
• Container-closure integrity
• In-use stability
• Extractables and leachables
• Visual appearance and particulate limits
• Naphazoline assay and degradation products
• Preservative content and effectiveness

A BAK-free product may reduce excipient-related tolerability concerns but increase dependence on specialized packaging. That shifts the competitive barrier from chemistry toward device engineering and supply-chain control.

What licensing opportunities exist for AK-CON?

The most attractive licensing targets are likely to be formulation and device technologies rather than naphazoline rights.

Potential deal structures include:

1. An exclusive ophthalmic license for a preservative-free multidose dispenser.
2. A regional license for a BAK-free naphazoline formulation.
3. A co-development agreement with an ophthalmic CDMO.
4. A technology-transfer agreement covering aseptic fill-finish and packaging.
5. A brand-and-generic partnership using a differentiated formulation to support premium pricing.

Licensing value would depend on freedom to operate, patent term, regulatory precedent, manufacturing scalability, and evidence of better tolerability. A formulation with no delivery-system protection would face rapid generic imitation.

What generic launch scenarios exist for AK-CON?

Three launch scenarios are commercially plausible.

Conventional generic launch

A generic manufacturer launches a standard preserved aqueous solution. This scenario creates rapid price competition and weak differentiation. Pharmacy substitution and wholesaler contracting would determine market share.

Premium BAK-free launch

A company launches a BAK-free product at a premium price. Adoption would depend on ophthalmologist prescribing, payer coverage, and evidence that patients experience fewer ocular-surface complaints.

Preservative-free specialty launch

A unit-dose or validated preservative-free multidose product targets chronic users and patients with ocular-surface disease. This model supports higher gross margins but carries greater packaging and distribution costs.

What is the revenue exposure and commercial upside?

The commercial value of AK-CON depends on the size of the prescription naphazoline market, the number of generic competitors, and the ability to move the product away from commodity pricing.

Revenue exposure is highest in the following areas:

• Existing sales dependent on a single BAK-preserved presentation
• Contracts requiring uninterrupted sterile ophthalmic supply
• Markets where generic substitution is permitted
• Hospital or pharmacy accounts with preservative-free preferences
• Product portfolios exposed to ophthalmic manufacturing constraints

The clearest upside comes from creating a differentiated product with a defensible formulation-device combination. A simple excipient substitution is unlikely to support durable premium pricing.

Key Takeaways

• AK-CON is a naphazoline hydrochloride 0.1% ophthalmic solution with a conventional BAK-preserved formulation.
• Its current excipient system includes benzalkonium chloride, borate buffers, sodium chloride, edetate disodium, purified water, and pH adjusters.
• The strongest commercial opportunity is a BAK-free or preservative-free reformulation.
• Preservative-free multidose delivery offers better convenience than unit-dose packaging but creates higher device and regulatory requirements.
• Naphazoline has limited molecule-level exclusivity value because it is an established active ingredient.
• Formulation, container, manufacturing, and narrow method-of-use patents are the most plausible sources of new protection.
• Generic competition is the principal risk if no active listed patent blocks ANDA entry.
• Licensing value is concentrated in ophthalmic delivery systems, sterile manufacturing, and validated low-irritation formulations.

FAQs

Can AK-CON be reformulated without benzalkonium chloride?

Yes. A reformulation could use unit-dose packaging, a validated preservative-free multidose dispenser, or an alternative preservative system. The product would require new stability, sterility, packaging, and regulatory assessments.

Is naphazoline hydrochloride still patent-protected?

The active ingredient is an established compound with limited practical composition-of-matter exclusivity. Any meaningful current protection would more likely relate to a specific formulation, delivery device, method of use, or manufacturing process.

Would a BAK-free AK-CON qualify for automatic generic substitution?

Not necessarily. Therapeutic-equivalence and substitution status would depend on the FDA-approved product, dosage form, inactive ingredients, reference listed drug, and applicable regulatory pathway.

Are unit-dose vials commercially attractive for AK-CON?

They can be attractive for patients who need preservative avoidance, but they carry higher packaging, shipping, filling, and waste costs. Their best fit is a specialty or ophthalmology-focused product rather than a low-price commodity generic.

Could AK-CON support a new method-of-use patent?

A method-of-use patent would need a specific, defensible clinical use and evidence supporting differentiation. A broad claim covering temporary relief of eye redness would face substantial prior-art and obviousness challenges.

References

1. DailyMed. (n.d.). AK-CON- naphazoline hydrochloride solution. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/

2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. U.S. Food and Drug Administration. (2023). Nasal decongestant and bronchodilator drug products for over-the-counter human use. Code of Federal Regulations, Title 21. https://www.ecfr.gov/

5. European Medicines Agency. (2009). Assessment report: Benzalkonium chloride used as an excipient. https://www.ema.europa.eu/